In clinical settings, KDM5A upregulation has been detected in EGFR-mutant NSCLC patient biopsies after EGFR-TKI treatment, and is associated with emergence of a drug-tolerant state (Shaffer et al., 2017). This evidence concerns the gene KDM5A and non-small cell lung carcinoma.